Jianxin Capital
Jianxin Capital is an investment fund based in Shanghai that specializes in risk investments within the healthcare sector. The firm is supported by a professional team of nearly 20 members, each possessing extensive experience in medical and financial fields. This diverse expertise enables the team to make informed investment decisions aligned with industry trends, aimed at generating value for both enterprises and investors. The members have backgrounds in biomedical and financial sectors, both domestically and internationally, allowing them to stay informed about developments in the biopharmaceutical industry. Jianxin Capital focuses on the specific needs of the companies it invests in, providing comprehensive support in areas such as product development, industrialization, management, and financial investment. Through these efforts, Jianxin Capital aims to contribute significantly to the growth and success of its portfolio companies.
21 past transactions
Hegea Bio
Series A in 2024
Hegeia Biotechnology is a company that focused on the research and development of siRNA, tiny nucleic acid attached delivery medicines.
Isabers
Series A in 2023
Isabers is a provider of advanced semiconductor integration technology and products, which can achieve inter-generational fusion of semiconductor materials and advanced packaging and can effectively solve the pain points of low yield, high cost, and limited performance of advanced semiconductor materials or devices, thus accelerating the development of the domestic semiconductor industry and quickly seizing the strategic high ground of international market competition.
Meike Solar
Series B in 2021
Meike Solar is a manufacturer specializing in the research and development of solar photovoltaic polycrystalline silicon wafers. The company employs integrated monitoring systems and equipment to enhance its manufacturing processes, allowing for efficient production at reduced costs. By focusing on advanced technologies and intelligent manufacturing, Meike Solar aims to contribute to the solar energy sector while optimizing operational efficiency.
Weishi Energy
Series A in 2021
Weishi Energy is a hydrogen fuel cell product research and development manufacturer, focusing on the market operation of hydrogen fuel cell technology, and is committed to promoting the low-carbon sustainable development of human energy. It is mainly engaged in the research and development, production and sales of hydrogen fuel cell products. At present, Weishi Energy has deployed five R&D centers in Shanghai, Baoding, Japan, Germany, and Canada. It has established a culturally diverse and technologically advanced R&D team, and strictly follows the V model development process to create vehicle-level fuel cell power systems and components. The company's main products include fuel cell engines, electric stacks, 35MPa/70MPa on-board hydrogen systems, bottle valves and pressure reducing valves, etc.
GeneCast Biotechnology
Series E in 2020
GeneCast Biotechnology Co., Ltd. is a Beijing-based company founded in 2014, specializing in gene research and cancer diagnostics. The company offers a technology platform for cell-free DNA next-generation sequencing (NGS) tests, which include companion diagnostics, genetic profiling, prognosis, and monitoring for various solid tumors. GeneCast provides solutions for cancer treatment and genetic testing, focusing on tumors such as lung, colorectal, liver, and breast cancers. Its non-invasive diagnostic methods leverage high-throughput sequencing and bioinformatics to enable personalized medicine, aiming to improve patient outcomes and quality of life. The company collaborates with hospitals and research institutions to advance its capabilities in detecting tumors and cancer-related genes in blood.
Abbisko Therapeutics
Series C in 2020
Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery, development, and manufacturing of innovative immuno-oncology therapies. Founded in 2016 by a team of experienced professionals from leading pharmaceutical companies, Abbisko is dedicated to developing small molecule inhibitors, including ABSK011 and ABSK021, for the treatment of hepatocellular carcinoma, as well as CSF1R for solid tumors. In addition to oncology, the company is engaged in developing therapeutics for various conditions, including cancer, liver diseases, diabetes, metabolic disorders, viral infections, and central nervous system diseases.
Percutek Therapeutics
Series D in 2019
Percutek Therapeutics is a manufacturer focused on the research, development, and production of minimally invasive interventional medical devices for cardiovascular applications. The company specializes in devices that facilitate non-invasive diagnosis and treatment of cardiovascular conditions, targeting areas such as the aorta, peripheral and coronary vasculature, as well as nerve intervention. Percutek Therapeutics is committed to delivering safe and effective solutions that enhance the treatment of vascular diseases, thereby improving patient outcomes in cardiovascular care.
Leads Biolabs
Venture Round in 2019
Leads Biolabs is a biotechnology company based in China that focuses on developing innovative antibody-based therapeutics for oncology and immunological diseases. Founded in 2014, the company is dedicated to addressing global unmet medical needs by creating biopharmaceutical products that enhance treatment outcomes for patients. Leads Biolabs has established a strong research and development pipeline, featuring over ten projects centered on monoclonal and bispecific antibodies aimed at cancer immunotherapy. Through its commitment to advancing tumor immunotherapy, the company strives to improve the medical treatment and overall conditions of patients facing cancer.
Innocare
Private Equity Round in 2019
InnoCare is a biopharmaceutical company based in China, focused on the discovery and development of innovative treatments for cancer and autoimmune diseases. The company boasts a highly skilled scientific team with extensive drug innovation experience in both the United States and China, supported by a distinguished Scientific Advisory Board composed of experts from top universities, hospitals, and the pharmaceutical industry. InnoCare's product pipeline includes a range of therapies, such as orelabrutinib, zanubrutinib, and tafasitamab, targeting hematological tumors, solid tumors, and autoimmune diseases. The company aims to make significant advancements in the treatment of conditions related to abnormal B-cell and T-cell functions, thereby contributing to the global fight against these diseases.
Leads Biolabs
Series B in 2018
Leads Biolabs is a biotechnology company based in China that focuses on developing innovative antibody-based therapeutics for oncology and immunological diseases. Founded in 2014, the company is dedicated to addressing global unmet medical needs by creating biopharmaceutical products that enhance treatment outcomes for patients. Leads Biolabs has established a strong research and development pipeline, featuring over ten projects centered on monoclonal and bispecific antibodies aimed at cancer immunotherapy. Through its commitment to advancing tumor immunotherapy, the company strives to improve the medical treatment and overall conditions of patients facing cancer.
Sumgen Biotech
Series A in 2018
Sumgen is an antibody drug developer focused on creating innovative therapeutic antibody drugs for the treatment of tumors and other diseases. The company specializes in immunotherapy and immunodiagnosis, employing advanced technologies such as computer-aided design and mammalian cell display to screen and optimize antibody candidates. By leveraging its unique research and development methodologies, Sumgen aims to produce effective antibody drugs that provide patients with targeted treatment options for major diseases, including cancer.
Eastern Biotech
Angel Round in 2018
Eastern Biotech, headquartered in Beijing, specializes in the development and manufacturing of pharmaceutical products. Its primary focus is on creating treatments for diabetes and obesity through extensive medical research. Additionally, the company has developed therapeutic solutions for immune diseases and cancer, leveraging its expertise in humanized monoclonal antibodies and vaccines.
Huadao Biopharma
Angel Round in 2017
Huadao Biopharma is a biomedical company focused on developing cellular immunotherapy technologies for oncology applications. The company specializes in CAR-T (chimeric antigen receptor-T) cell technologies and employs advanced techniques such as bacteria fermentation engineering, virus purification, T cell acquisition, and cell harvesting. By providing healthcare practitioners with essential research resources and expertise, Huadao Biopharma aims to enhance treatment options for acute lymphoblastic leukemia and related diseases.
Leads Biolabs
Series A in 2017
Leads Biolabs is a biotechnology company based in China that focuses on developing innovative antibody-based therapeutics for oncology and immunological diseases. Founded in 2014, the company is dedicated to addressing global unmet medical needs by creating biopharmaceutical products that enhance treatment outcomes for patients. Leads Biolabs has established a strong research and development pipeline, featuring over ten projects centered on monoclonal and bispecific antibodies aimed at cancer immunotherapy. Through its commitment to advancing tumor immunotherapy, the company strives to improve the medical treatment and overall conditions of patients facing cancer.
Abbisko Therapeutics
Series A in 2017
Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery, development, and manufacturing of innovative immuno-oncology therapies. Founded in 2016 by a team of experienced professionals from leading pharmaceutical companies, Abbisko is dedicated to developing small molecule inhibitors, including ABSK011 and ABSK021, for the treatment of hepatocellular carcinoma, as well as CSF1R for solid tumors. In addition to oncology, the company is engaged in developing therapeutics for various conditions, including cancer, liver diseases, diabetes, metabolic disorders, viral infections, and central nervous system diseases.
FDOG
Angel Round in 2015
FDOG is a pet-growth assistant app that provides customize pet-raising reminders.
Shejia
Angel Round in 2015
Shejia is an app for second-hand luxury goods.
LP Pharmaceuticals
Series A in 2015
LP Pharmaceuticals (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.
Jia.com
Series B in 2015
Jia.com is a leading interior designing platform specializing in home decoration services. Established in March 2005 by Shanghai Qijia Information Technology Co., Ltd., the company offers a wide range of products including decorations, building materials, furniture, appliances, and mass consumer goods. By June 2010, Jia.com had amassed over 1.8 million registered members and conducted more than 2,000 group buying events, serving over 5 million customers. The platform has attracted nearly 12,000 businesses and 15,000 brands, processing over 1.2 million valid orders annually with a total output value exceeding 3.2 billion Yuan.
ChanGee
Private Equity Round in 2012
ChanGee is medical manufacturing company that develops medical products including surgical masks, syringes and medicines.
Hair & Yard
Series C in 2011
Hair & Yard is a hair product manufacturing company.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.